|
1
|
Sangeetha Menon A, Subasic de Azevedo I, Choong K, Bhatnagar D, Wang C, Sluka P, Chisholm DR, Pasic P, Thissen H, Sama G, Robinson A, Rodda A, Tria A, Spiegel L, Dharma A, Kaipananickal H, Okabe J, El-Osta A, Mountford S, Thompson P, Dear AE. Advances in Design and Development of Lumi-Solve: A Novel Drug-Eluting Photo-Angioplasty Device. Cardiovasc Eng Technol 2023; 14:605-614. [PMID: 37165253 PMCID: PMC10465377 DOI: 10.1007/s13239-023-00668-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Accepted: 04/24/2023] [Indexed: 05/12/2023]
Abstract
PURPOSE The Lumi-Solve photo-angioplasty drug eluting balloon catheter (DEBc) may afford safety advantages over current DEBc. Lumi-Solve utilises the guidewire (GW) port and lumen to deliver fibre-optic UV365nm light to the angioplasty balloon which may be problematic. We explore and evaluate alternative Lumi-Solve design options to circumvent fibre-optic use of the GW port and lumen which may enhance efficacy and clinical utility. METHODS Effects of guidewire shadowing (GWS) on visible and UV365nm light transmission were evaluated and modelled in-silico. To evaluate the effect of a dedicated intra-balloon fibre-optic port, modified angioplasty balloons and sections of translucent polyethylene terephthalate (PET) GW port tubing were utilised. Investigation of the effect of GWS on chemical and biological photo-activation of balloon surface drug was performed utilising LCMS analysis and inhibition of histone deacetylase activity (HDACi) was measured in human umbilical vein endothelial cells (HUVEC). RESULTS Parallel fibre-optic and GW port configurations generated a GWS of approximately 18.0% of the evaluable balloon surface area and attenuated both visible and UV light intensity by 20.0-25.0% and reduced chemical photo-activation of balloon surface drug and HDACi by at least 40-45%. Alternative fibre-optic port configurations including a spiral design significantly mitigated GWS effects on UV light transmission. CONCLUSIONS To avoid use of the GW port and its associated complications a dedicated third port and lumen for the Lumi-Solve fibre-optic may be required. To maximize balloon surface chemical and biological photo-activation, non-parallel, intra-balloon, fibre-optic lumen trajectories, including a spiral design may be useful.
Collapse
Affiliation(s)
| | | | - Kylie Choong
- Eastern Health Clinical School, Monash University, Melbourne, Australia
| | - Dhruv Bhatnagar
- Eastern Health Clinical School, Monash University, Melbourne, Australia
| | - Chen Wang
- Eastern Health Clinical School, Monash University, Melbourne, Australia
| | - Pavel Sluka
- Eastern Health Clinical School, Monash University, Melbourne, Australia
| | | | - Paul Pasic
- CSIRO Biomedical Materials Translational Facility, Melbourne, Australia
| | - Helmut Thissen
- CSIRO Biomedical Materials Translational Facility, Melbourne, Australia
| | - Gopal Sama
- School of Chemistry, Monash University, Melbourne, Australia
| | - Andrea Robinson
- School of Chemistry, Monash University, Melbourne, Australia
| | - Andrew Rodda
- Monash Institute of Medical Engineering, Monash University, Melbourne, Australia
| | - Aldous Tria
- Monash Institute of Medical Engineering, Monash University, Melbourne, Australia
| | - Loren Spiegel
- Monash Institute of Medical Engineering, Monash University, Melbourne, Australia
| | - Anak Dharma
- Monash Institute of Medical Engineering, Monash University, Melbourne, Australia
| | | | - Jun Okabe
- Monash University Department of Diabetes, Monash University, Melbourne, Australia
| | - Assam El-Osta
- Monash University Department of Diabetes, Monash University, Melbourne, Australia
| | - Simon Mountford
- Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
| | - Philip Thompson
- Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
| | - Anthony E Dear
- Eastern Health Clinical School, Monash University, Melbourne, Australia.
- Department of Vascular Surgery, Eastern Health, Box Hill Hospital, Melbourne, Australia.
| |
Collapse
|
|
2
|
Liu H, Sama GR, Robinson A, Mountford S, E Thompson P, Rodda A, Forsythe J, Mornane PJ, Pasic P, Thissen H, Byrne M, Kaye DM, Dear AE. Design, Development, In Vitro and Preliminary In Vivo Evaluation of a Novel Photo-Angioplasty Device: Lumi-Solve. Cardiovasc Eng Technol 2021; 12:466-473. [PMID: 33709249 DOI: 10.1007/s13239-021-00525-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Accepted: 02/08/2021] [Indexed: 11/30/2022]
Abstract
PURPOSE Paclitaxel (PTX)-coated drug eluting balloon catheters (DEBc) used in the management of neointimal hyperplasia (NIH) have been associated with safety concerns. Alternative coating agents and targeted delivery systems may improve safety and DEBc efficacy. Utilizing a multi-platform approach we designed, developed and evaluated Lumi-Solve, a novel DEBc, coated with ultraviolet (UV) 365 nm-activated caged metacept-3 (c-MCT-3), an epigenetic agent from the histone deacetylase inhibitor (HDACi) class. METHODS In vitro catheter and contrast media transmission of UV365nm was evaluated spectroscopically. UV365nm conversion of c-MCT-3 to MCT-3 was evaluated chromatographically. Cellular toxicity and HDACi activity of c-MCT-3 ∓UV365nm was evaluated in vitro. In vivo UV365nm conversion of c-MCT-3 to MCT-3 was evaluated in an ovine carotid artery model. RESULTS Catheter material and dilute contrast media did not attenuate UV365nm transmission or c-MCT-3 activation. c-MCT-3 demonstrated less cellular toxicity than MCT-3 and PTX. UV365nm-activated c-MCT-3 demonstrated HDACi activity. In vivo activation of c-MCT-3 produced MCT-3. CONCLUSIONS Lumi-Solve, a novel DEBc device developed utilizing a combination of chemical, fibre-optic and catheter based technology platforms, demonstrated potential for targeted delivery of bioactive HDACi to the blood vessel wall supporting direct application to the management of NIH and warranting additional in vivo studies.
Collapse
Affiliation(s)
- HongBin Liu
- Eastern Health Clinical School, Monash University, Box Hill, Australia
| | - Gopal R Sama
- Department of Chemistry, Monash University, Clayton, Australia
| | - Andrea Robinson
- Department of Chemistry, Monash University, Clayton, Australia
| | - Simon Mountford
- Monash Institute of Pharmaceutical Sciences, Monash University, Clayton, Australia
| | - Philip E Thompson
- Monash Institute of Pharmaceutical Sciences, Monash University, Clayton, Australia
| | - Andrew Rodda
- Monash Institute of Medical Engineering, Monash University, Clayton, Australia
| | - John Forsythe
- Monash Institute of Medical Engineering, Monash University, Clayton, Australia
| | | | - Paul Pasic
- CSIRO Biomedical Translational Facility, Melbourne, Australia
| | - Helmut Thissen
- CSIRO Biomedical Translational Facility, Melbourne, Australia
| | - Melissa Byrne
- Baker Heart and Diabetes Institute, Melbourne, Australia
| | - David M Kaye
- Baker Heart and Diabetes Institute, Melbourne, Australia
| | - Anthony E Dear
- Eastern Health Clinical School, Monash University, Box Hill, Australia.
| |
Collapse
|